Italy Rare Biomarkers Specimen Collection And Stabilization Market Size & Outlook

The rare biomarkers specimen collection and stabilization market in Italy is expected to reach a projected revenue of US$ 3,701.6 million by 2030. A compound annual growth rate of 12.8% is expected of Italy rare biomarkers specimen collection and stabilization market from 2025 to 2030.
Revenue, 2024 (US$M)
$1,822.0
Forecast, 2030 (US$M)
$3,701.6
CAGR, 2025 - 2030
12.8%
Report Coverage
Italy

Italy rare biomarkers specimen collection and stabilization market, 2018-2030 (US$M)

Italy
Unlock Premium

Related Markets

Italy rare biomarkers specimen collection and stabilization market highlights

  • The Italy rare biomarkers specimen collection and stabilization market generated a revenue of USD 1,822.0 million in 2024 and is expected to reach USD 3,701.6 million by 2030.
  • The Italy market is expected to grow at a CAGR of 12.8% from 2025 to 2030.
  • In terms of segment, circulating cell free dna (ccfdna) was the largest revenue generating biomarker in 2024.
  • Circulating Cell Free RNA (ccfRNA) / miRNA is the most lucrative biomarker segment registering the fastest growth during the forecast period.

Rare biomarkers specimen collection and stabilization market data book summary

Market revenue in 2024USD 1,822.0 million
Market revenue in 2030USD 3,701.6 million
Growth rate12.8% (CAGR from 2025 to 2030)
Largest segmentCirculating cell free dna (ccfdna)
Fastest growing segmentCirculating Cell Free RNA (ccfRNA) / miRNA
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCirculating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes/Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA
Key market players worldwideQiagen NV, Charles River Laboratories International Inc, Roche Holding AG ADR, Thermo Fisher Scientific Inc, Eurofins Scientific SE, PerkinElmer, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Merck KGaA, Siemens Healthineers AG ADR

Other key industry trends

  • In terms of revenue, Italy accounted for 4.3% of the global rare biomarkers specimen collection and stabilization market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany rare biomarkers specimen collection and stabilization market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 4,111.8 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Rare Biomarkers Specimen Collection And Stabilization Market Companies

Name Profile # Employees HQ Website

Italy rare biomarkers specimen collection and stabilization market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare biomarkers specimen collection and stabilization market will help companies and investors design strategic landscapes.


Circulating cell free dna (ccfdna) was the largest segment with a revenue share of 39.52% in 2024. Horizon Databook has segmented the Italy rare biomarkers specimen collection and stabilization market based on circulating cell free dna (ccfdna), circulating tumor cells (ctcs), exosomes/extracellular vesicles, circulating cell free rna (ccfrna) / mirna covering the revenue growth of each sub-segment from 2018 to 2030.


Presence of labs, such as GENOMA GROUP laboratories, that perform PrenatalSAFE Karyo, an NIPT, i s anticipated to positively impact the revenue growth i n the country. Furthermore, several initiatives are being undertaken to advance the use of liquid biopsy tests i n this country. In March 2019, MDxHealth SA’s SelectMDx liquid biopsy test, which i s developed for detection of prostate cancer was included i n the 2019 Italian Society of Urology (SIU) guidelines. This achievement i s expected to boost the use of SelectMDx i n this country. This, i n turn, would directly impact the sales of rare biomarker isolation kits i n the country 

Reasons to subscribe to Italy rare biomarkers specimen collection and stabilization market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Italy rare biomarkers specimen collection and stabilization market databook

  • Our clientele includes a mix of rare biomarkers specimen collection and stabilization market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Italy rare biomarkers specimen collection and stabilization market , including forecasts for subscribers. This country databook contains high-level insights into Italy rare biomarkers specimen collection and stabilization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Italy rare biomarkers specimen collection and stabilization market size, by biomarker, 2018-2030 (US$M)

Italy Rare Biomarkers Specimen Collection And Stabilization Market Outlook Share, 2024 & 2030 (US$M)

Italy rare biomarkers specimen collection and stabilization market size, by biomarker, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more